Job Opportunities API

The Public Ledger of Openings

← Back to the ledger

Director, Investor Relations

Jade Biosciences
CompanyJade Biosciences
CategoryFinance
LocationBoston; Remote; San Francisco; Seattle; Vancouver
RemoteRemote
EmploymentNot stated
LevelDirector
SalaryNot stated by the employer
Posted3 Aug 2026
Last verified11 Aug 2026
SourceEmployer ATS (greenhouse)
Applications are handled by the employer, not by us.Apply on the employer's site →
Description
About Jade Biosciences   Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody candidate, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit  JadeBiosciences.com  and follow the Company on  LinkedIn .   Role Overview   Jade Biosciences is seeking a Director, Investor Relations to help build and execute a high caliber investor relations function for a publicly traded biotechnology company. The Director will play a central role in communicating Jade’s strategy, pipeline, scientific rationale, clinical development progress, financial position, and value proposition to a primarily investor audience, including institutional investors, sell-side analysts, bankers, and other capital markets stakeholders.   This role requires a strong understanding of biotechnology equity markets, clinical-stage company strategy, and investor-facing communications. The ideal candidate will be able to translate complex scientific, clinical, regulatory, and financial information into clear, credible, and compelling messaging for sophisticated external audiences. Former sell-side biotechnology research professionals are encouraged to apply, including candidates who served as research associates supporting biotechnology or healthcare coverage.   This is a remote role reporting to the Chief Financial Officer and will require periodic travel for investor conferences, investor roadshows, medical and scientific meetings, company meetings, and Board or leadership events.     Key Responsibilities   Support the development and execution of Jade’s investor relations strategy in partnership with the CFO, CEO, and senior leadership team.   Develop and refine investor messaging, Q&A, presentation materials,  SEC filings,  earnings or corporate update materials, investor conference materials, and other external communications.   Serve as a key point of contact for investors and sell-side analysts, helping ensure  timely ,  accurate , consistent, and  Regulation  FD-compliant communications.   Translate complex scientific, clinical, regulatory, competitive, and financial information into clear investor-facing narratives tailored to public market audiences.   Monitor investor sentiment, analyst commentary, trading dynamics, peer company disclosures, competitive developments, sector trends, and relevant clinical or regulatory catalysts.   Prepare briefing materials for executive leadership ahead of investor meetings, conferences, roadshows, analyst calls, and other external engagements.   Help  maintain  and enhance the company’s investor materials, including the corporate presentation, investor website content, fact sheets, event calendars, and FAQ documents.   Partner cross- functionally  with Finance, Legal, Clinical Development, Regulatory, Medical, Corporate Communications, and external advisors to ensure alignment of investor communications.   Assist  with quarterly reporting processes, including call preparation, scripts, press releases, Q&A preparation, and post-call investor feedback synthesis.   Support capital  markets  activities, investor targeting, ownership analysis, conference stra